[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368664-105":59,"doc-detail-368664-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","rad51-and-palb2-in-precision-oncology-clinical-implications-for-hrd-associated-breast-and-ovarian-cancers-review","RAD51 and PALB2 in precision oncology - Clinical implications for HRD associated breast and ovarian cancers - Review","","Maintaining genomic stability is essential for reducing carcinogenesis risk. Homologous recombination (HR) is a high-fidelity DNA repair mechanism addressing double-strand breaks and interstrand crosslinks. This review examines RAD51 and PALB2 in precision oncology, detailing their structural and functional roles in breast and ovarian cancer. Mutations impair HR, increasing susceptibility to multiple cancers and reducing treatment efficacy. Clinical consequences cover risk stratification, PARP inhibitor performance, emerging therapies, and the potential of RAD51/PALB2 as biomarkers and therapeutic targets.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rad51-and-palb2-in-precision-oncology-clinical-implications-for-hrd-associated-breast-and-ovarian-cancers-review/368664/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rad51-and-palb2-in-precision-oncology-clinical-implications-for-hrd-associated-breast-and-ovarian-cancers-review/368664.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What roles do RAD51 and PALB2 play in homologous recombination (HR)?","Question",{"text":113,"@type":114},"RAD51 facilitates homology search and strand invasion, while PALB2 links BRCA1 and BRCA2 and stabilizes RAD51 filaments to support HR.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do RAD51 and PALB2 mutations affect cancer and treatment outcomes?",{"text":118,"@type":114},"Mutations compromise HR, increasing susceptibility to cancers and impacting treatment efficacy by impairing DNA repair, which can alter responses to therapies such as PARP inhibitors.",{"name":120,"@type":111,"acceptedAnswer":121},"Which clinical themes does the review address for HRD-associated breast and ovarian cancers?",{"text":122,"@type":114},"It covers clinical implications including risk stratification, PARP inhibitor efficacy, emerging therapies, and the use of RAD51/PALB2 as potential biomarkers and therapeutic targets.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368664,1790195034,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","INTERNATIONAL JOURNAL OF ONCOLOGY 67: 65, 2025  \nRAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review)  \nMOHD ADNAN KAUSAR 1 , KHALID FARHAN ALSHAMMARI2 , FAHAADALENAZI3 , SADAF ANWAR 1 , AMANY MOHAMMED KHALIFA4 , TARIG GINAWI 1 , ABDULAZIZ ASIRI5 , MOHAMMAD ZEESHAN NAJM6 , SYED ARMAN RABBANI7 , MOHAMED EL‑TANANI8 and SAUMYATIKAGANTAYAT6  \n1Department of Biochemistry, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia; 2Department of Internal Medicine, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia; 3Department of Pharmacology, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia; 4Department of Pathology, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia; 5Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha 67714, Saudi Arabia; 6School of Biosciences, Apeejay Stya University, Gurugram, Haryana 122103, India; 7Department of Clinical Pharmacy and Pharmacology, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates; 8RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates  \nReceived April 7, 2025; Accepted June 3, 2025  \nDOI: 10.3892/ijo.2025.5771  \nAbstract. Maintaining genomic stability is essential for reducing the risk of carcinogenesis . Homologous recombi‑ nation (HR) is a high‑fidelity DNA repair mechanism that addresses double‑strand breaks and interstrand crosslinks . The present review examined two key components of HR: RAD51, the eukaryotic recombinase and PALB2 , a scaf‑ folding protein . Their structural and functional roles are explored in the context of breast and ovarian cancer. RAD51 facilitates homology search and strand invasion, while PALB2 links BRCA1 and BRCA2 , stabilizing RAD51 fila‑ ments. Mutations in these genes compromise HR, increasing susceptibility to various cancers and impacting treatment efficacy by impairing DNA repair. The present review discussed the clinical implications of RAD51 and PALB2 mutations, focusing on risk stratification, PARP inhibitor efficacy and emerging therapies. Additionally, it highlighted the potential of RAD51 and PALB2 as biomarkers and therapeutic targets, contributing to advances in personalized cancer management.  \nCorrespondence to: Professor Mohd Adnan Kausar, Department of Biochemistry, College of Medicine, University of Ha'il, 53962 Al Khitah Street, Hail 2440, Saudi Arabia  \nEmail: [adnankausar1@gmail.com](adnankausar1@gmail.com); [ma.kausar@uoh.edu.sa](ma.kausar@uoh.edu.sa)  \n[Key words:](Key words: RAD51)[ RAD51](Key words: RAD51), PALB2, BRCA, breast cancer, ovarian cancer, HRR, PARP inhibitors, theragnostic, genetic testing  \nContents  \n1. Introduction  \n2. Domain organization  \n3. Molecular functions  \n4. Synergistic interaction with other HRR genes  \n5. Antagonistic interactions with other HRR genes  \n6. RAD51 and PALB2 and its association with various types of cancer  \n7. Mutational landscape of RAD51 and PALB2  \n8. Clinical significance of RAD51 and PALB2 in breast and ovarian cancer  \n9. Therapeutic implications  \n10. Commercial insights  \n11. Limitations  \n12. Conclusion  \n1. Introduction  \nCancer develops due to genetic and epigenetic alterations that disrupt normal cellular functions, leading to uncontrolled prolif‑ eration and genomic instability. As the second leading cause of global mortality, its incidence continues to rise, driven by errors in cell division, environmental exposures (such as tobacco smoke and UV radiation) and inherited mutations (1). Among the most prevalent malignancies, breast cancer is the most frequently diagnosed cancer in women worldwide, whereas ovarian cancer, although less common, has a higher fatality rate (2). According to the World Health Organization, the global incidence of these cancers is projected to rise from 2.62 million i","cbCaiq5x1o1lRJPO","https://ap.wps.com/l/cbCaiq5x1o1lRJPO","pdf",2125767,16,"English","# Contents\n## 1. Introduction\n## 2. Domain organization\n## 3. Molecular functions\n## 4. Synergistic interaction with other HRR genes\n## 5. Antagonistic interactions with other HRR genes\n## 6. RAD51 and PALB2 and its association with various types of cancer\n## 7. Mutational landscape of RAD51 and PALB2\n## 8. Clinical significance of RAD51 and PALB2 in breast and ovarian cancer\n## 9. Therapeutic implications\n## 10. Commercial insights\n## 11. Limitations\n## 12. Conclusion","[{\"question\":\"What roles do RAD51 and PALB2 play in homologous recombination (HR)?\",\"answer\":\"RAD51 facilitates homology search and strand invasion, while PALB2 links BRCA1 and BRCA2 and stabilizes RAD51 filaments to support HR.\"},{\"question\":\"How do RAD51 and PALB2 mutations affect cancer and treatment outcomes?\",\"answer\":\"Mutations compromise HR, increasing susceptibility to cancers and impacting treatment efficacy by impairing DNA repair, which can alter responses to therapies such as PARP inhibitors.\"},{\"question\":\"Which clinical themes does the review address for HRD-associated breast and ovarian cancers?\",\"answer\":\"It covers clinical implications including risk stratification, PARP inhibitor efficacy, emerging therapies, and the use of RAD51/PALB2 as potential biomarkers and therapeutic targets.\"}]","RAD51 and PALB2 in precision oncology - Clinical implications for HRD associated breast and ovarian cancers - Review | PDF",1790177925,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14d78be94e1c4c21897645eb2c33db0a.webp",983,1357,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e812a80b21d1bf5212de952958da814.webp",982,1356,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fcf90abfeaf1635bdeda54e9557f8da.webp",981,1354,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/357bdef4787934be31f60ba64a326ff0.webp",980,1353]